CU6 · ASX

Clarity Pharmaceuticals Ltd. (ASX:CU6)

AU$3.5

 0.07 (2.041%)
ASX:Live
21/02/2025 04:10:56 PM
HALO Small HALO Ords HALO Consensus Value HALO 200 GROWTH AUS +3
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

CU6 Overview

CU6 Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Very Strong

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Neutral

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Neutral

About CU6

Website

N/A

Telephone

61.2.9209.4037

Address

4 Cornwallis Street National Innovation Centre Eveleigh, New South Wales (NSW) 2015

Description

Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.

CU6 Price Chart

Key Stats

Market Cap

AU$1.10B

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 2.49 - 8.98

Trade Value (12mth)

AU$2,116,888.00

1 week

3.94%

1 month

-12.05%

YTD

-15.52%

1 year

28.38%

All time high

8.98

Key Fundamentals

EPS 3 yr Growth

289.20%

EBITDA Margin

N/A

Operating Cashflow

-$43m

Free Cash Flow Return

-40.10%

ROIC

-39.30%

Interest Coverage

N/A

Quick Ratio

19.00

Other Data

Shares on Issue (Fully Dilluted)

281m

HALO Sector

Healthcare

Next Company Report Date

20-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

2.91

CU6 Announcements

Latest Announcements

Date Announcements

19 February 25

Clarity receives US FDA FTD for the treatment of mCRPC

×

Clarity receives US FDA FTD for the treatment of mCRPC

18 February 25

Response to ASX Cleansing Notice Timing Letter

×

Response to ASX Cleansing Notice Timing Letter

11 February 25

Clarity expands pipeline with Cu-64/67 SAR-trastuzumab

×

Clarity expands pipeline with Cu-64/67 SAR-trastuzumab

11 February 25

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

11 February 25

Cleansing Notice

×

Cleansing Notice

31 January 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

29 January 25

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

29 January 25

Cleansing Notice

×

Cleansing Notice

28 January 25

Clarity to present COBRA and CLARIFY abstracts

×

Clarity to present COBRA and CLARIFY abstracts

24 January 25

Clarity receives U.S. FDA Fast Track Designation

×

Clarity receives U.S. FDA Fast Track Designation

22 January 25

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

22 January 25

Cleansing Notice

×

Cleansing Notice

08 January 25

Notification of cessation of securities - CU6

×

Notification of cessation of securities - CU6

18 December 24

Novel FAP-targeted radiopharmaceutical

×

Novel FAP-targeted radiopharmaceutical

18 December 24

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

18 December 24

Cleansing Notice

×

Cleansing Notice

06 December 24

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

06 December 24

Cleansing Notice

×

Cleansing Notice

06 December 24

S&P DJI Announces December 2024 Quarterly Rebalance

×

S&P DJI Announces December 2024 Quarterly Rebalance

28 November 24

Last patient assessment completed for SARTATE trial

×

Last patient assessment completed for SARTATE trial

26 November 24

Change of Director's Interests - All Directors

×

Change of Director's Interests - All Directors

26 November 24

First 2 participants dosed with Cu-64 SAR-bisPSMA in Co-PSMA

×

First 2 participants dosed with Cu-64 SAR-bisPSMA in Co-PSMA

25 November 24

Notification regarding unquoted securities - CU6

×

Notification regarding unquoted securities - CU6

20 November 24

AGM MD Presentation

×

AGM MD Presentation

20 November 24

Chairperson Address AGM

×

Chairperson Address AGM

CU6 Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.10 -0.09 -0.15 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.10 -0.09 -0.15 Lock Lock Lock
     Growth % Lock Lock Lock Lock -140.2 1.2 -63.9 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.06 -0.09 -0.12 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.05 -0.11 -0.16 Lock Lock Lock
     Growth % Lock Lock Lock Lock -82.5 -54.0 -37.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -10.7 -15.2 -3.0 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.36 0.26 0.47 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.36 0.26 0.47 Lock Lock Lock
     Growth % Lock Lock Lock Lock 351.7 -25.8 77.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 248 260 273 Lock Lock Lock
Basic m Lock Lock Lock Lock 248 260 273 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 30 36 56 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -196.0 -117.3 -52.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -30 -36 -56 Lock Lock Lock
     Growth % Lock Lock Lock Lock -119.3 -21.9 -55.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -30 -36 -56 Lock Lock Lock
     Growth % Lock Lock Lock Lock -119.4 -22.0 -55.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -30 -34 -54 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -6 -10 -11 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -24 -25 -42 Lock Lock Lock
     Growth % Lock Lock Lock Lock -132.4 -3.6 -72.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -13 -27 -43 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -27 3 -55 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 87 0 115 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -14 -28 -44 Lock Lock Lock
     Growth % Lock Lock Lock Lock -74.8 -103.6 -58.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 92 65 137 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 100 77 155 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -92 -65 -137 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 8 8 8 Lock Lock Lock
Equity $m Lock Lock Lock Lock 92 69 146 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 92 69 146 Lock Lock Lock
     Growth % Lock Lock Lock Lock 354.9 -25.0 111.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -23.8 -32.0 -27.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -25.8 -35.6 -28.9 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -52.7 -44.8 -52.3 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -42.2 -30.5 -39.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -23.7 -34.1 -40.1 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 3.1 1.8 2.4 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -100.1 -94.0 -93.3 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 13.3 10.2 19.0 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 13.3 10.2 19.0 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 92.8 84.8 88.6 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -177.4 -364.6 -534.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -23.8 -32.0 -27.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -25.8 -35.6 -28.9 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -25.8 -35.6 -28.9 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 12,126.2 10,339.9 5,877.6 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -12,126.2 -10,339.9 -5,877.6 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

2.91%

Value ($M)

31

Prior Change

0.10%

7 Day Change

0.30%

1 Month Change

0.70%

3 Month Change

2.40%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CU6 Shortsell

Frequently Asked Questions

The current share price of Clarity Pharmaceuticals Ltd. (CU6:ASX) is AU$3.5.
The 52-week high share price for Clarity Pharmaceuticals Ltd. (CU6:ASX) is AU$8.98.
The 52-week low share price for Clarity Pharmaceuticals Ltd. (CU6:ASX)? is AU$2.49.
Clarity Pharmaceuticals Ltd. (CU6:ASX) does not pay a dividend.
Clarity Pharmaceuticals Ltd. (CU6:ASX) does not pay a dividend.
Clarity Pharmaceuticals Ltd. (CU6:ASX) has a franking level of 0.0%.
Clarity Pharmaceuticals Ltd. (CU6:ASX) is classified in the Healthcare.
The current P/E ratio for Clarity Pharmaceuticals Ltd. (CU6:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.